Brief Article
Copyright ©2010 Baishideng.
World J Gastroenterol. Feb 28, 2010; 16(8): 997-1002
Published online Feb 28, 2010. doi: 10.3748/wjg.v16.i8.997
Table 1 Clinicopathological features of patients with stage II pancreatic adenocarcinoma (mean ± SD) n (%)
ParametersWith vascular resection (n = 12)Without vascular resection (n = 75)P value
Age (yr)62.9 ± 11.062.9 ± 9.80.994
Gender0.745
Male7 (58.3)50 (66.7)
Female5 (41.7)25 (33.3)
Symptoms
Jaundice6 (50.0)55 (73.3)0.171
Abdominal pain6 (50.0)35 (46.7)0.830
Body weight loss6 (50.0)31 (41.3)0.573
Anorexia3 (25.0)17 (22.7)1.000
Signs
Anemic4 (33.3)38 (50.7)0.265
Icterus6 (50.0)54 (72.0)0.178
Abdominal tenderness3 (25.0)15 (20.0)0.707
Albumin (g/dL)3.9 ± 0.63.7 ± 0.50.205
Total bilirubin (mg/dL)6.8 ± 7.08.9 ± 7.10.333
Pre-op biliary drainage0.573
Yes6 (50.0)44 (58.7)
No6 (50.0)31 (41.3)
CEA (ng/mL)1.000
≤ 55 (62.5)36 (62.1)
> 53 (37.5)22 (37.9)
CA19-9 (U/mL)0.411
≤ 373 (33.3)13 (21.0)
> 376 (66.7)49 (79.0)
Operation time (min)473.9 ± 185.2461.6 ± 110.40.826
Blood transfusion (mL)396 ± 588304 ± 5900.618
Tumor size (cm)3.6 ± 1.63.3 ± 1.40.526
Lymph node metastases0.097
Yes8 (66.7)65 (86.7)
No4 (33.3)10 (13.3)
Curability0.015
Yes12 (100.0)48 (64.0)
No0 (0.0)27 (36.0)
Postoperative chemotherapy0.436
Yes8 (66.7)41 (54.7)
No4 (33.3)34 (45.3)
Table 2 Morbidity and mortality in patients with stage II pancreatic adenocarcinoma n (%)
ParametersWith vascular resection (n = 12)Without vascular resection (n = 75)
Morbidity6/12 (50.0)30/75 (40.0)
Pancreatic leakage2 (16.7)9 (12.0)
Pancreatic fistula0 (0.0)8 (10.7)
Gastrointestinal bleeding1 (8.3)6 (8.0)
Pleural effusion2 (8.3)4 (5.3)
Delayed gastric emptying1 (8.3)3 (4.0)
Wound infection0 (0.0)4 (4.0)
Intra-abdominal abscess0 (0.0)4 (5.3)
Bile leakage1 (8.3)3 (4.0)
Sepsis0 (0.0)3 (4.0)
Intra-abdominal bleeding1 (8.3)2 (2.7)
Mortality0 (0.0)2 (2.7)
Table 3 Univariate analyses of predictive factors for survival of patients with stage II adenocarcinoma of the pancreas after PD or PPPD, with or without vascular resection
ParametersMedian (mo)95% CI of median3-yr survival (%)P value
Age (yr)0.852
≤ 70 (n = 62)11.517.78-15.2512.0
> 70 (n = 23)9.409.15-9.6516.3
Sex0.191
Male (n = 55)9.767.61-11.919.6
Female (n = 30)14.013.20-24.8219.4
Albumin (g/dL)0.107
≤ 3.5 (n = 21)7.403.86-10.9412.7
> 3.5 (n = 47)11.675.96-17.3812.8
Total bilirubin (mg/dL)0.008
≤ 2 (n = 19)17.3915.23-19.5530.7
> 2 (n = 65)9.407.66-11.143.5
Serum CA 19-9 (U/L)0.167
≤ 37 (n = 16)16.111.47-30.7525.0
> 37 (n = 54)11.518.17-14.8512.3
Serum CEA (ng/mL)0.455
≤ 5 (n = 40)16.0810.78-21.3813.4
> 5 (n = 24)7.825.18-10.46.16.7
Blood transfusion0.491
Yes (n = 47)10.887.17-14.5914.9
No (n = 38)9.245.59-12.899.8
Tumor size (cm)
≤ 3 (n = 43)13.9710.77-17.1813.30.508
> 3 (n = 41)9.278.82-9.7212.5
Nodal metastases0.557
Yes (n = 71)9.767.69-11.8313.6
No (n = 14)12.160.00-28.368.3
Pre-op biliary drainage0.262
Yes (n = 49)9.247.80-10.6812.0
No (n = 36)13.979.44-18.5014.3
PV/SMV resection0.994
Yes (n = 12)9.270.00-19.5416.7
No (n = 73)10.367.87-12.8612.2
Resection margin10.071
Negative (n = 58)11.516.46-16.5616.1
Positive (n = 27)9.277.46-11.085.1
Differentiation0.016
Well (n = 25)20.989.02-32.9424.0
Moderately (n = 45)8.817.81-9.818.8
Poorly (n = 15)10.497.01-13.976.7
Adjuvant chemotherapy0.008
Yes (n = 53)12.9910.44-12.7418.8
No (n = 32)7.965.74-10.193.2
Table 4 Multivariate analysis in stage II pancreatic adenocarcinoma of the head and uncinate process
ParametersHazard ratio (95% CI)P value
Bilirubin (mg/dL)
≤ 2/> 22.024 (1.613-3.774)0.026
Differentiation0.005
Moderately/well2.412 (1.379-4.217)0.002
Poorly/well2.091 (1.034-4.225)0.040
Adjuvant chemotherapy
No/yes2.068 (1.270-3.366)0.003
PV/SMV resection
Yes/no0.591